Alzheimer's Hope

School Principal and mother-of-five, Catherine Lockhart contacted the Baker Institute recently after she saw our research featured on Channel Ten’s program, The Project (watch the clip).

She wanted to share how Alzheimer’s disease had changed her mum’s life.

“My mum passed away from Alzheimer’s and it was a terrible way to go. There's nothing you can do. All of a sudden, they don't know who you are. You grieve for a long time, and you feel like you lost them long before they die,” shared Catherine.

In a world-leading study, our Metabolomics lab has discovered that fats in the blood are linked with the onset of vascular disease (including heart attack and stroke), diabetes, and in a groundbreaking first, Alzheimer’s.

Project leader and Head of Metabolomics, Professor Peter Meikle, explains:
“Lipids — fats in the blood — are helping us to understand the metabolic changes associated with metabolic diseases. They could be used as markers to identify people at risk and provide a therapeutic pathway to prevention.”

I’m sure you agree that this incredible breakthrough could bring hope to millions of Australians, just like Catherine.

“Not to be able to remember our loved ones or not to be able to share memories with loved ones in their final years is just so painful and so difficult. That’s why this research is so important, and my hope is that something can be done to stop this from happening to other families.”
— Catherine Lockhart

Our goal is that within a few years, we will be able to predict an accurate risk score for specific conditions, all from a drop of blood.

But we urgently need to raise $120,000 to fund the first 3000 tests before the end of April 2021.

Your support today will really help Professor Peter Meikle and his team progress to the next stage of their research.

 

 

The blood test researchers at the Baker Institute has been developing aims to provide a risk score to help people better understand how well their metabolism is working.

We know now that understanding metabolism is important for a range of chronic diseases.

By being able to evaluate a patient’s metabolic age, doctors will be able to clearly communicate an individual’s disease risk and track specifically how medications or lifestyle changes can help lower their risk.

Professor Peter Meikle further reveals:

“We now have the potential to identify people at high risk of developing metabolic disease, such as Alzheimer’s, before they show clinical symptoms. This is important because early detection will enable early treatment, which is the best opportunity to delay or prevent the onset of most disease.”

This incredible discovery could improve millions of lives not just in Australia, but also around the world. What is even more encouraging, is just how close we are to seeing this research translate from the laboratory into clinical practice.

With your support today, predicting the onset of diseases like heart disease, diabetes, and even Alzheimer’s, could be just a few years away.

 

 

 

Big data

Coralie, loving mother and grandmother

Tragically, around 460,000 Australians have dementia and Alzheimer’s disease accounts for up to 70 percent of all diagnosed cases.

 

In Australia, 1 in 10 people above the age of 65 will develop Alzheimer’s disease, a degenerative condition of the brain that affects memory and cognitive function.

 

 

Big data

Coralie and Barry

 

 

Big data

Coralie with her daughters Juanita and Catherine